For decades, a diagnosis of vanishing white matter disease came with no real treatment — so how is an old blood-pressure pill offering hope? In this episode of In Conversation With…The Lancet Neurology, Deputy Editor Laura Hart speaks with Professor Marjo van der Knaap (Amsterdam UMC) about her clinical trial of guanabenz in children with the leukodystrophy vanishing white matter. They unpack the integrated stress response and eIF2B pathophysiology, why guanabenz moved from mouse models into a paediatric trial, the striking effect of age of onset, unexpected hallucinations as a side-effect, and where combination therapy with eIF2B activators could take the field. Essential listening for neurologists on leukodystrophy, rare paediatric neurological disease, and translating stress-response biology into treatment.

Click here to read the full article:

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00241-3/fulltext

In this episode, Heather Brown, Senior Editor at The Lancet Neurology, chats with Jan Lünemann (University of British Columbia, Canada) and Christian Münz (University of Zürich, Switzerland) about their Rapid Review on Epstein-Barr virus (EBV) and multiple sclerosis (MS).

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00177-8/fulltext

In this episode of In Conversation With, Morgane Boillot, Senior Editor at The Lancet Neurology, speaks with connective tissue disorders — including Marfan syndrome — and human genetics expert Hal Dietz from Johns Hopkins Medicine (Baltimore, USA) about the genetics of spontaneous spinal CSF leaks.

Together, they explore the clinical presentation, diagnosis, and current treatment of spontaneous spinal CSF leaks, and discuss genetic findings revealing rare deleterious variants in FBN2, the gene encoding fibrillin-2, in patients with type 1b leaks. The conversation covers translational and mechanistic findings — including CRISPR-Cas9 mouse models and cellular interactions with the extracellular matrix — and what these reveal about the underlying biology of fibrillin-1 and fibrillin-2-related disorders. It also addresses the potential clinical implications of these findings, and Professor Dietz shares his hopes for their use in therapeutic development.

Click here to read the full article:

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00140-7/fulltext

In this episode of In Conversation With, Elena Becker-Barroso, Editor-in-Chief of The Lancet Neurology, speaks with movement disorders specialist Tony Schapira from UCL’s Queen Square Institute of Neurology about GBA1-associated Parkinson’s disease.

Click here to read the full article:

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00090-6/fulltext

Join The Lancet Neurology’s In Conversation With… as editors Elena Becker-Barroso and Laura Hart welcome Henry Brodaty and Alice Powell from the University of New South Wales (Sydney, Australia) to discuss cognitive resilience and ageing.

This episode teases apart cognitive resilience, cognitive reserve, brain maintenance, and brain reserve; explores how social determinants, life-course factors, and vascular health shape resilience; and delves into robust measures, biomarkers, and how pathologies interact with resilience. It also covers multicomponent interventions and their transferability to low-income and middle-income countries, how clinicians should communicate risk, and the key knowledge gaps and priorities for global cognitive resilience research. Don’t miss this timely exploration of dementia prevention and healthy brain ageing.

Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00027-X/fulltext

In this episode, Laura Hart and Elena Becker-Barroso speak with Niklas Mattsson-Carlgren (Lund University) about the use of blood biomarkers in the diagnosis and stratification of Alzheimer's disease. They discuss two particular plasma biomarkers—p-tau217 and eMTBR-tau243—including what they measure and how a proposed practical two-step approach that uses p-tau217 as an initial screen in a neurology clinic, and then eMTBR-tau243 for those who test positive, could support diagnostic decisions. 

Click here to read the full article:

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00029-3/fulltext

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!

In this episode, Senior Editor Morgane Boillot speaks with Professor Cristina Tassorelli (University of Pavia, Italy) about recent advances in migraine prevention. 

In this conversation, they explore what these advances mean for people living with migraine and for clinicians, discuss promising emerging targets for prevention and the future of biomarkers, and consider whether it is time to redefine the goals of migraine prevention with greater ambition. 

Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00477-6/fulltext

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!

Our Editor-in-Chief, Elena Becker-Barroso, speaks with Inga Zerr (DZNE, Göttingen, Germany) and Simon Mead (UCL London, UK) about the latest advances in prion diseases. 

In collaboration with other experts, Zerr and Mead have authored a Series in the journal that covers the genetic factors behind these diseases, and new diagnostic and prognostic biomarkers.

Click here to read the full articles:

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00451-X/fulltext

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!

Host Morgane Boillot chats with Dr Julia Greenland about a clinical trial of azathioprine in early Parkinson's disease. 

Click here to read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00386-2/fulltext

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!

In this episode, host Antonia Eisenkoeck, speaks with Ian McKeith, Emeritus Professor of Old Age Psychiatry at Newcastle University, UK. They delve into the history of dementia with Lewy bodies research, highlighting key milestones and breakthroughs. Discover insights into the current state of the field and what the future holds for understanding and treating this condition.

Click here to read the full articles of this series:

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00363-1/fulltext

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00323-0/fulltext

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00314-X/fulltext

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!